Source disclosure: March 05, 2026, 16:30 JST
Published by Pulse News Wire: March 05, 2026, 16:34 JST
Nxera Pharma Co.,Ltd. [4565.T]
TOKYO, Mar 05 (Pulse News Wire) – Nxera Pharma CO.,LTD. (4565.T) announced today that it has received an additional milestone payment of $3 million (approximately ¥473 million) from its partner, Centessa Pharmaceuticals Limited, related to the development of ORX489, an OX2R agonist targeting neurodegenerative diseases.
This payment follows the initial milestone disclosed on February 13, 2026. Under their research collaboration agreement, the entire amount will be recognized as revenue in the first quarter of the fiscal year ending December 2026. The impact of this milestone payment on Nxera Pharma's consolidated performance for the fiscal year ending December 2026 has already been incorporated into the forecast released on February 13, 2026.
Nxera Pharma is a technology-driven biopharmaceutical company focused on addressing unmet medical needs globally through innovative specialty medicines. The company operates agile next-generation commercial businesses across broad markets in Japan and APAC, leveraging multiple approved products and pioneering drug development programs. Utilizing its proprietary “NxWave™” drug discovery platform, Nxera Pharma advances more than 30 programs spanning early exploration to late-stage clinical trials, prioritizing key unmet needs in growing therapeutic areas such as obesity, metabolic disorders, neurological and neuropsychiatric conditions, and immune and inflammatory diseases.
AI-translated content. 🟢 Confidence: High See terms • Original filing